Identifying recurrences and metastasis after ductal carcinoma in situ (DCIS) of the breast
Open Access
- 8 December 2022
- journal article
- review article
- Published by Wiley in Histopathology
- Vol. 82 (1) , 106-118
Abstract
Ductal carcinoma in situ (DCIS) of the breast is a non-invasive tumour that has the potential to progress to invasive ductal carcinoma (IDC). Thus, it represents a treatment dilemma: alone it does not present a risk to life, however, left untreated it may progress to a life-threatening condition. Current clinico-pathological features cannot accurately predict which patients with DCIS have invasive potential, and therefore clinicians are unable to quantify the risk of progression for an individual patient. This leads to many women being over-treated, while others may not receive sufficient treatment to prevent invasive recurrence. A better understanding of the molecular features of DCIS, both tumour-intrinsic and the microenvironment, could offer the ability to better predict which women need aggressive treatment, and which can avoid therapies carrying significant side-effects and such as radiotherapy. In this review, we summarise the current knowledge of DCIS, and consider future research directions.Keywords
Funding Information
- Cancer Australia (GNT2002944)
- National Breast Cancer Foundation (IIRS‐18‐051)
- National Health and Medical Research Council (GNT1193630)
- Peter MacCallum Foundation
This publication has 129 references indexed in Scilit:
- A Multigene Expression Assay to Predict Local Recurrence Risk for Ductal Carcinoma In Situ of the BreastJNCI: Journal of the National Cancer Institute, 2013
- HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situBritish Journal of Cancer, 2012
- Association of RB/p16-Pathway Perturbations with DCIS RecurrenceThe American Journal of Pathology, 2011
- Long-Term Outcomes of Invasive Ipsilateral Breast Tumor Recurrences After Lumpectomy in NSABP B-17 and B-24 Randomized Clinical Trials for DCISJNCI: Journal of the National Cancer Institute, 2011
- Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trialThe Lancet Oncology, 2011
- Prevalence of BRCA1 and BRCA2 Mutations in Women with Breast Carcinoma In Situ and Referred for Genetic TestingCancer Prevention Research, 2010
- Biomarker Expression and Risk of Subsequent Tumors After Initial Ductal Carcinoma In Situ DiagnosisJNCI: Journal of the National Cancer Institute, 2010
- Ductal Carcinoma In Situ of the Breast: A Systematic Review of Incidence, Treatment, and OutcomesJNCI: Journal of the National Cancer Institute, 2010
- Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinomaBreast Cancer Research, 2008
- Biological markers that predict clinical recurrence in ductal carcinoma in situ of the breastEuropean Journal of Cancer, 2003